FLORENCE, Italy and NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc.

Study results demonstrated that in adult patients with blastic plasmacytoid dendritic cell neoplasm, the targeted therapy resulted in high response rates, particularly among treatment-naïve patients.

Blastic plasmacytoid dendritic-cell neoplasm (BPDCN) is an aggressive hematologic cancer that is caused by transformed plasmacytoid dendritic cells that overexpress interleukin-3 receptor subunit ...

Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with intermediate or high risk relapsed/refractory myelofibrosis. This is an ASCO Meeting Abstract from the 2019 ASCO ...

An open-label, multi-cohort Phase II trial, led by investigators at The University of Texas MD Anderson Cancer Center, reports that treatment with the drug tagraxofusp resulted in high response rates ...

Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Clinical trials frequently include multiple end ...

$43.2 million in estimated ELZONRIS net revenues for the year-ended December 31, 2019 $11.8 million in estimated ELZONRIS net revenues for the fourth quarter of 2019 The above financial information is ...

NICE is unable to make a recommendation about the use in the NHS of tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm. This is because Stemline Therapeutics has confirmed that it ...

As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm. The company that makes ...